Details for Patent: 8,003,681

Which drugs does patent 8,003,681 protect, and when does it expire?

Patent 8,003,681 protects DUZALLO and ZURAMPIC and is included in two NDAs.

This patent has fifty-seven patent family members in thirty-three countries.

Summary for Patent: 8,003,681

Title:	2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acet- ic acid and methyl ester
Abstract:	A series of S-triazolyl .alpha.-mercaptoacetanilides having general structure (1) are provided, where Q is CO.sub.2H, CONR.sub.2, SO.sub.3H, or SO.sub.2NR.sub.2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections. ##STR00001##
Inventor(s):	Girardet; Jean-Luc (San Diego, CA), Koh; Yung-Hyo (Irvine, CA)
Assignee:	Ardea Biosciences, Inc. (San Diego, CA)
Application Number:	12/633,638
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 8,003,681

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ironwood Pharms Inc	DUZALLO	allopurinol; lesinurad	TABLET;ORAL	209203-001	Aug 18, 2017		DISCN	Yes	No				Y
Ironwood Pharms Inc	DUZALLO	allopurinol; lesinurad	TABLET;ORAL	209203-002	Aug 18, 2017		DISCN	Yes	No				Y
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No				Y

International Family Members for US Patent 8,003,681

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E528001
Austria	E540677
Australia	2005280130
Australia	2009217458
Brazil	PI0514630
Brazil	PI0520870